PDCD1 and hepatocellular carcinoma: Previous studies have shown that immune checkpoint inhibitors, including anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies, have shown potential therapeutic promise for advanced HCC (Zongyi and Xiaowu, 2020).